Bosentan

Type: Product
Name: Bosentan
First reported Oct 21 2014 - Updated Oct 21 2014 - 2 reports

Actelion's (ALIOF) CEO Jean-Paul Clozel on Q3 2014 Results - Earnings Call Transcript

Actelion Limited ( OTCPK:ALIOF ) Q3 2014 Earnings Conference Call October 21, 2014 8:00 AM ETOperatorGood afternoon. This is the Arkadin conference operator. Welcome to the Actelion’s Nine Months 2014 Financial Results Conference Call. As a reminder, ... [Published Seeking Alpha - Oct 21 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 6 reports

Actelion Reports Strong Q3 Results, Says It Has Not Received Any Acquisition Offers From US Pharma Giants

Actelion reported strong financials for 3QFY14. The company further said that it has not received any acquisition offers from US-based pharmaceutical companies, at the same time indicating that it has no plans to entertain any such offersPage 1 of 2Click ... [Published Bidness Etc - Oct 21 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

UPDATE 1-Actelion raises full-year profit view on strong Opsumit launch

* Q3 product sales 496 mln Sfr vs 492 mln in poll* Q3 Opsumit sales 59 mln Sfr* Raises full-year core earnings guidance* Now expects core earnings growth in low twenties pctgerange* Says selexipag filing "very close"(Adds details)ZURICH, Oct 21 (Reuters) ... [Published Reuters UK - Oct 21 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

PAH: Understanding the Three New Drug Therapies

IntroductionEditor's Note : Pulmonary arterial hypertension (PAH) is historically an incurable disease with a poor prognosis. However, recent advances in treating PAH have increased arsenal of treatments available to the physician for managing its sy ... [Published General Medicine eJournal - Oct 08 2014]
First reported Oct 04 2014 - Updated Oct 04 2014 - 1 reports

Researchers Submit Patent Application, "Method for Treating Pulmonary Arterial Hypertension in a Patient Not Having Idiopathic Pulmonary Fibrosis",...

Researchers Submit Patent Application, "Method for Treating Pulmonary Arterial Hypertension in a Patient Not Having Idiopathic Pulmonary Fibrosis", for ApprovalBy a News Reporter-Staff News Editor at Biotech Week -- From Washington, D.C. , NewsRx journalists ... [Published 4 Traders - Oct 04 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

A Look At Arena's Other Drug

Summary Arena Pharmaceuticals is developing APD811 for treatment of pulmonary arterial hypertension or PAH, a rare disease. The drug has been granted an Orphan drug status by the FDA and the company is looking to advance it to a Phase II trial. PAH ... [Published Seeking Alpha - Oct 03 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Human medicines European public assessment report (EPAR): Stayveer, bosentan monohydrate, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Stayveer. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical ... [Published European Medicines Agency - Oct 02 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

United Therapeutics Points to Pluristem's PLX-PAD as its Most Transformative Product

Pulmonary arterial hypertension (PAH), a progressive and life threatening illness that regrettably takes a back seat to cardiovascular disease where research is concerned, is incurable and fatal. Characterized by high blood pressure in the arteries of ... [Published BioMedReports - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Sarcoid-Associated Pulmonary Hypertension and Lung Transplant

Cordova FC, D'Alonzo G. Sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med 2013;19(5):531–537Battesti JP, Georges R, Basset F, Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978;33(1):76–84Głuskowski J, Hawryłkiewicz ... [Published General Medicine eJournal - Sep 15 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Industry up in arms against NPPA for bringing 108 non-scheduled drugs under price control

The pharmaceutical industry in the country is up in arms against the recent notification of the National Pharmaceutical Pricing Authority (NPPA) in which the national drug price regulator has brought prices of 108 non-scheduled formulation packs involving ... [Published PharmaBiz - Jul 15 2014]
First reported May 08 2014 - Updated May 08 2014 - 2 reports

Orphan designation: Bosentan, for the: Treatment of systemic sclerosis (scleroderma)

Entities: Bosentan, scleroderma

Quotes

"People will have to be very careful in their acquisitions," he told Bloomberg. "I'm very happy with this new evolution. I do hope that people make acquisitions because of the value of the companies and not because of tax."
...of its pulmonary arterial hypertension (PAH) therapy Opsumit, which recorded sales of 59 million Swiss francs ($63 million) in the third quarter. "Opsumit's strong launch momentum continues as we gain...market share and continue to roll out the product in all major markets" commented chief operating officer Otto Schwarz
Jean-Paul Clozel, MD, Chief Executive Officer, commented: "Actelion continues to make significant progress. We are launching Opsumit successfully around the globe and we are very close to filing selexipag with healthcare authorities in the EU and the US. With these two new assets we can strengthen our leadership in PAH and continue to create value for all stakeholders."
"Prognosis for patients has really improved quite considerably with the advances that have been made in medication" says Robin Bhattacherjee, general manager at Actelion Pharmaceuticals UK

More Content

All (20) | News (17) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Actelion's (ALIOF) CEO Jean-Paul Clozel on Q3 2... [Published Seeking Alpha - Oct 21 2014]
Actelion beats expectations as third-qtr net pr... [Published Pharma Letter - Oct 21 2014]
It's back to basics in M&A, and that's a good t... [Published FiercePharma - Oct 21 2014]
Actelion Reports Strong Q3 Results, Says It Has... [Published Bidness Etc - Oct 21 2014]
Actelion Raises 2014 Forecast as New Lung Drug ... [Published Washington Post - Oct 21 2014]
Actelion lifts 2014 profit view on strong Opsum... [Published Sharenet - Oct 21 2014]
Actelion lifts annual earnings guidance on "str... [Published FirstWord Pharma - Oct 21 2014]
UPDATE 1-Actelion raises full-year profit view ... [Published Reuters UK - Oct 21 2014]
Actelion Raises Full-Year Forecast as Profit Ad... [Published Bloomberg - Oct 21 2014]
Actelion delivers strong nine months results [Published InfoStor - Oct 21 2014]
A new ERA for pulmonary arterial hypertension p... [Published Pharmaceutical Technology - Oct 13 2014]
PAH: Understanding the Three New Drug Therapies [Published General Medicine eJournal - Oct 08 2014]
Researchers Submit Patent Application, "Method ... [Published 4 Traders - Oct 04 2014]
A Look At Arena's Other Drug [Published Seeking Alpha - Oct 03 2014]
Human medicines European public assessment repo... [Published European Medicines Agency - Oct 02 2014]
United Therapeutics Points to Pluristem's PLX-P... [Published BioMedReports - Sep 17 2014]
Sarcoid-Associated Pulmonary Hypertension and L... [Published General Medicine eJournal - Sep 15 2014]
Industry up in arms against NPPA for bringing 1... [Published PharmaBiz - Jul 15 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.